⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 26, 2026JAMA Health ForumOpen Access

GLP-1 Prescriptions for Weight Loss by Differences in Insurance Plan Coverage

Mahnum Shahzad Protima Advani Oluwayomi Akintola MICHAEL CHERNEW

View Full Paper

Ask AI

Bookmark

Share

Key Points

To analyze the trends in GLP-1 prescriptions based on whether insurance plans cover these medications for weight loss.
Cross-sectional study design
Comparison of GLP-1 prescriptions between plans that cover and do not cover GLP-1s
Analysis of prescription trends over time
Increased GLP-1 prescriptions correlate with insurance coverage for weight loss
Lower prescription rates observed in plans without GLP-1 coverage
Variations in prescriptions highlight the impact of insurance on medication access for weight loss

Implication

Cross-sectional study reports trends in GLP-1 prescriptions linked to insurance coverage for weight loss.

Abstract

This cross-sectional study reports trends in glucagon-like peptide-1 (GLP-1) prescriptions for plans that do and do not cover GLP-1s for weight loss.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shahzad et al. (2026) studied this question.

synapsesocial.com/papers/6a40b9f361bb0a67205c6092 https://doi.org/10.1001/jamahealthforum.2026.1838

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns2025 · 62 citations
2A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight managementCross-Sectional Study · 2026
3Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany2024 · 18 citations
4The Role of GLP-1 Agonists in Weight Management: Barriers, Effectiveness, and Safety PerceptionsOriginal Research · 2026
5Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes2024 · 170 citations

More related papers

GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials2026
GLP-1 Receptor Agonist Prescriptions for Adolescents With Obesity and Associated Disparities2026
275 Patient perspectives on GLP-1 receptor agonists for weight loss: A mixed-methods study to inform translational obesity care2026

More from JAMA Health Forum

The “Safer” Plastics ParadoxFri,
Local Wealth Inequality and Working-Age Mortality in US CountiesFri,